-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Keji Pharmaceutical-B (02171.HK) announced that CT1190B, a general-purpose CAR-T cell product targeting CD19/CD20, has been approved by IND from the National Drug Administration to treat patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least second-line standard treatment. The results of the CT1190B IIT study were presented on a poster at the 2026 European Society of Hematology Annual Meeting.

Zhitongcaijing·08/07/2026 00:17:06
Listen to the news
Zhitong Finance App News, Keji Pharmaceutical-B (02171.HK) announced that CT1190B, a generic CAR-T cell product targeting CD19/CD20, has been approved by IND from the National Drug Administration to treat patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least second-line standard treatment. The results of the CT1190B IIT study were presented on a poster at the 2026 European Society of Hematology Annual Meeting.